Literature DB >> 30986486

The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.

Manuela A Hoffmann1, Helmut J Wieler2, Christian Baues3, Nicholas J Kuntz4, Ines Richardsen5, Mathias Schreckenberger6.   

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (CaP). PSMA-expression correlates with higher serum levels of prostate-specific antigen (PSA) and a higher Gleason score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). This article reviews the literature pertaining to various new imaging technologies for the management of CaP. PSMA positron emission tomography/computed tomography appears to be an excellent diagnostic tool, that may drastically impact the management of a large number of patients with primary and recurrent CaP.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30986486     DOI： 10.1016/j.urology.2019.04.004

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  16 in total

1.  [Oncological theranostics in nuclear medicine].

Authors:  Christina Laschinsky; Ken Herrmann; Wolfgang Fendler; Michael Nader; Harald Lahner; Boris Hadaschik; Patrick Sandach
Journal:  Radiologie (Heidelb)       Date:  2022-10

2.  Introduction of salvage prostatectomy in Denmark: the initial experience.

Authors:  Mike Allan Mortensen; Charlotte Aaberg Poulsen; Göran Ahlgren; Kirsten Madsen; Mads Hvid Poulsen
Journal:  BMC Res Notes       Date:  2022-05-21

3.  Triple combination therapy for clinically nonmetastatic super-high-risk prostate cancer.

Authors:  Koji Yoshimura; Kei Muraoka; Michiko Fukasawa; Mika Fukushima; Masatoshi Kumagai; Ryo Yabusaki; Masakatsu Ueda; Yusuke Shiraishi; Masaaki Imamura
Journal:  IJU Case Rep       Date:  2022-05-13

Review 4.  Prostate cancer.

Authors:  Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow
Journal:  Nat Rev Dis Primers       Date:  2021-02-04       Impact factor: 52.329

5.  Clinical Utility of 18F-PSMA-1007 Positron Emission Tomography/Magnetic Resonance Imaging in Prostate Cancer: A Single-Center Experience.

Authors:  Ao Liu; Miao Zhang; Hai Huang; Chuanjie Zhang; Xiaohao Ruan; Wenhao Lin; Biao Li; Lu Chen; Danfeng Xu
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

6.  The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors:  Manuela A Hoffmann; Hans-Georg Buchholz; Helmut J Wieler; Thomas Höfner; Jonas Müller-Hübenthal; Ludwin Trampert; Mathias Schreckenberger
Journal:  Oncotarget       Date:  2019-10-22

7.  Improved oncological outcome after radical prostatectomy in patients staged with 68Ga-PSMA-11 PET: a single-center retrospective cohort comparison.

Authors:  Daniela A Ferraro; Fabienne Lehner; Daniel Eberli; Irene A Burger; Anton S Becker; Benedikt Kranzbühler; Ken Kudura; Iliana Mebert; Michael Messerli; Thomas Hermanns
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-19       Impact factor: 9.236

8.  Systematic review & meta-analysis of positron emission tomography/computed tomography and bone scan in the diagnosis of prostate lesions.

Authors:  Jiafu Wang; Yue Han; Lin Lin; Linhan Zhang; Jin Li; Huiqi Gao; Peng Fu
Journal:  Transl Androl Urol       Date:  2021-11

9.  Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis.

Authors:  Yi Zhao; Naomi Morka; Benjamin Scott S Simpson; Alex Freeman; Alex Kirkham; Daniel Kelly; Hayley C Whitaker; Mark Emberton; Joseph M Norris
Journal:  BMJ Open       Date:  2021-12-10       Impact factor: 2.692

10.  Differences in Distribution and Detection Rate of the [68Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11-Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer.

Authors:  Falk Gühne; Stefanie Radke; Thomas Winkens; Christian Kühnel; Julia Greiser; Philipp Seifert; Robert Drescher; Martin Freesmeyer
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.